A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate


Wittman, Brenda, Horan, John, Baxter, Joanna, Goldberg, John, Felgar, Raymond, Baylor, Erin, Cromwell, Bean, Cross, Nicholas and Bennett, John M. (2004) A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate Leukemia Research, 28, (Supplement 1), pp. 65-69. (doi:10.1016/j.leukres.2003.10.011).

Download

Full text not available from this repository.

Description/Abstract

Atypical chronic myelogenous leukemia (aCML) is a myelodysplastic/myeloproliferative disorder that usually occurs in older adults. Here we report a pediatric patient with aCML and a t(5;12)(q33;p13) with a corresponding fusion gene ETV6-PDGFRB. Because the PDGFRB tyrosine kinase is one of the known targets of tyrosine kinase inhibitors, this patient achieved cytogenetic and molecular remission with treatment with imatinib mesylate (formerly STI571; now Gleevec in the United States and Glivec in Europe). This case illustrates one of many myelodysplastic/myeloproliferative disorders that can be treated with this particular tyrosine kinase inhibitor.

Item Type: Article
Digital Object Identifier (DOI): doi:10.1016/j.leukres.2003.10.011
ISSNs: 0145-2126 (print)
Subjects:
ePrint ID: 60436
Date :
Date Event
May 2004Published
Date Deposited: 19 Nov 2008
Last Modified: 16 Apr 2017 17:32
Further Information:Google Scholar
URI: http://eprints.soton.ac.uk/id/eprint/60436

Actions (login required)

View Item View Item